Yeah, I mean, I think, you know, the cool thing about ctDNA is obviously something that’s being looked at across all solid tumors. We haven’t had as many studies in endometrial cancer, and to my knowledge, this report from DUO-E is one of the first reports of ctDNA in a large phase three randomized study in the advanced and recurrent settings, so we’re happy to add to the literature there...
Yeah, I mean, I think, you know, the cool thing about ctDNA is obviously something that’s being looked at across all solid tumors. We haven’t had as many studies in endometrial cancer, and to my knowledge, this report from DUO-E is one of the first reports of ctDNA in a large phase three randomized study in the advanced and recurrent settings, so we’re happy to add to the literature there. I think broadly across cancer in general, utilizing ctDNA for monitoring and for understanding response to therapy is increasing. And so we’ve definitely needed more research in this space to truly understand how it might help guide decision making around is a patient, does a patient need more therapy? Or does a patient, you know, are they getting benefit from the therapy? Or do we need to move on to a different therapy? So I don’t know that we’re quite there yet. But I think this study in addition to other studies that are starting to report out will really help us understand the importance of ctDNA monitoring and how it might be used in clinical practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
